Altimmune (ALT) EBITDA Yield: History & Chart

Altimmune, Inc.(ALT)

Biotechnology · Gaithersburg, MD

$2.69+0.02 (+0.56%)

Delayed quote: Oct 6, 2026, 3:00 PM EDT

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

57 employees

altimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jerome Benedict Durso

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Altimmune, Inc. (ALT)	$522.16M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$523.04M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$520.33M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$526.07M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$510.36M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$535.43M	N/A	1.23%	1.23%	1.23%
Allogene Therapeutics, Inc. (ALLO)vs ›	$509.10M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$509.12M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$534.18M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$536.32M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Altimmune, Inc. (ALT)

$522.16M

N/A

Aclaris Therapeutics, Inc. (ACRS)vs ›

$523.04M

N/A

BlossomHill Therapeutics, Inc. (BLSM)vs ›

$520.33M

N/A

Immix Biopharma, Inc. (IMMX)vs ›

$526.07M

N/A

Crescent Biopharma, Inc. (CBIO)vs ›

$510.36M

N/A

Delcath Systems, Inc. (DCTH)vs ›

$535.43M

N/A

1.23%

Allogene Therapeutics, Inc. (ALLO)vs ›

$509.10M

N/A

908 Devices Inc. (MASS)vs ›

$509.12M

N/A

Nuvectis Pharma, Inc. (NVCT)vs ›

$534.18M

N/A

ProKidney Corp. (PROK)vs ›

$536.32M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

ALT EBITDA Yield Metrics

ALT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics